ACLY and hyperlipidemia: Supporting the role of ACLY inhibition to promote healthy aging, several ACLY inhibitors have been developed and investigated in the pathophysiology of several age‐related diseases, including cancer, hepatic steatosis, hyperlipidemia, and diabetes (Hatzivassiliou et al., 2005; Morrow et al., 2022; Sanjay et al., 2021; Verrelli et al., 2022), and the ACLY inhibitor Bemp has been shown to be safe and effective lowering circulating cholesterol levels in the clinic (Pinkosky et al., 2013; Ray et al., 2019; Ruscica et al., 2022).